LY-517717 Uses, Dosage, Side Effects and more
LY517717 is an investigational oral direct inhibitor of activated Factor Xa. It is believed to be Lilly's PMD-3112 (licensed from Amgen).
LY517717 has been well tolerated in healthy subjects. LY517717 is a blood thinner that may prevent blood clots from forming in the legs and may prevent those blood clots from traveling to the lungs. Leg and lung blood clots occur commonly after patients have surgery to replace a hip or knee joint. These clots often occur while patients are in bed in the hospital after hip or knee joint surgery.
| Attribute | Details |
|---|---|
| Trade Name | LY-517717 |
| Generic | LY-517717 |
| Type | |
| Formula | C27H33N5O2 |
| Weight | Average: 459.594 Monoisotopic: 459.263425323 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in thrombosis and venous thromboembolism.
How LY-517717 works
LY517717, an investigational oral direct inhibitor of activated Factor Xa, appears to interrupt thrombus formation without impairing platelet hemostatic function.
